| Literature DB >> 30641954 |
Weihua Jin1, Wanli Wu2, Hong Tang3, Bin Wei4, Hong Wang5, Jiadong Sun6,7, Wenjing Zhang8, Weihong Zhong9.
Abstract
Sulfated galactofucan (ST-2) was obtained from Sargassum thunbergii. It was then desulfated to obtain ST-2-DS, and autohydrolyzed and precipitated by ethanol to obtain the supernatant (ST-2-S) and precipitate (ST-2-C). ST-2-C was further fractionated by gel chromatography into two fractions, ST-2-H (high molecular weight) and ST-2-L (low molecular weight). Mass spectrometry (MS) of ST-2-DS was performed to elucidate the backbone of ST-2. It was shown that ST-2-DS contained a backbone of alternating galactopyranose residues (Gal)n (n ≤ 3) and fucopyranose residues (Fuc)n. In addition, ST-2-S was also determined by MS to elucidate the branches of ST-2. It was suggested that sulfated fuco-oligomers might be the branches of ST-2. Compared to the NMR spectra of ST-2-H, the spectra of ST-2-L was more recognizable. It was shown that ST-2-L contain a backbone of (Gal)n and (Fuc)n, sulfated mainly at C4 of Fuc, and interspersed with galactose (the linkages were likely to be 1→2 and 1→6). Therefore, ST-2 might contain a backbone of (Gal)n (n ≤ 3) and (Fuc)n. The sulfation pattern was mainly at C4 of fucopyranose and partially at C4 of galactopyranose, and the branches were mainly sulfated fuco-oligomers. Finally, the anti-tumor and anti-angiogenic activities of ST-2 and its derivates were determined. It was shown that the low molecular-weight sulfated galactofucan, with higher fucose content, had better anti-angiogenic and anti-tumor activities.Entities:
Keywords: Sargassum thunbergii; anti-angiogenic activity; anti-tumor activity; fucoidan; sulfated galactofucan
Mesh:
Substances:
Year: 2019 PMID: 30641954 PMCID: PMC6356460 DOI: 10.3390/md17010052
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1IR spectra of ST-2 (A), ST-2-DS (B), ST-2-H (C), and ST-2-L (D).
Figure 2Negative-ion mode ESI-MS spectrum of ST-2-DS.
Proposed compositions of the ions of desulfated ST-2 (ST-2-DS).
| Charge | Composition | Charge | Composition | ||
|---|---|---|---|---|---|
| 257.032 | 1 | [Me Fuc(SO3H)-H]− | 330.024 | 2 | [Me Gal2Fuc(SO3H)2-2H]2− |
| 403.089 | 1 | [Me Fuc2(SO3H)-H]− | 807.309 | 1 | [Me Gal2Fuc2(SO3H)2-H]− |
| 549.146 | 1 | [Me Fuc3(SO3H)-H]− | 476.059 | 2 | [Me Gal2Fuc3(SO3H)2-2H]2− |
| 695.203 | 1 | [Me Fuc4(SO3H)-H]− | 419.084 | 1 | [Me GalFuc(SO3H)-H]− |
| 841.261 | 1 | [Me Fuc5(SO3H)-H]− | 565.141 | 1 | [Me GalFuc2(SO3H)-H]− |
| 987.318 | 1 | [Me Fuc6(SO3H)-H]− | 711.198 | 1 | [Me GalFuc3(SO3H)-H]− |
| 1133.374 | 1 | [Me Fuc7(SO3H)-H]− | 857.257 | 1 | [Me GalFuc4(SO3H)-H]− |
| 1279.434 | 1 | [Me Fuc8(SO3H)-H]− | 1003.316 | 1 | [Me GalFuc5(SO3H)-H]− |
| 1425.493 | 1 | [Me Fuc9(SO3H)-H]− | 581.136 | 1 | [Me Gal2Fuc(SO3H)-H]− |
| 389.073 | 1 | [Fuc2(SO3H)-H]− | 727.193 | 1 | [Me Gal2Fuc2(SO3H)-H]− |
| 535.130 | 1 | [Fuc3(SO3H)-H]− | 873.251 | 1 | [Me Gal2Fuc3(SO3H)-H]− |
| 681.188 | 1 | [Fuc4(SO3H)-H]− | 1019.305 | 1 | [Me Gal2Fuc4(SO3H)-H]− |
| 827.247 | 1 | [Fuc5(SO3H)-H]− | 743.188 | 1 | [Me Gal3Fuc(SO3H)-H]− |
| 973.303 | 1 | [Fuc6(SO3H)-H]− | 889.244 | 1 | [Me Gal3Fuc2(SO3H)-H]− |
| 1119.361 | 1 | [Fuc7(SO3H)-H]− | 1035.302 | 1 | [Me Gal3Fuc3(SO3H)-H]− |
| 160.991 | 2 | [Fuc(SO3H)2-2H]2− | 347.032 | 2 | [Fuc3(SO3H)3-2H]2− |
| 182.332 | 3 | [Fuc2(SO3H)3-3H]3− | 380.084 | 2 | [Fuc4(SO3H)2-2H]2− |
| 234.022 | 2 | [Fuc2(SO3H)2-2H]2− | 469.049 | 1 | [Fuc2(SO3H)2-H]− |
| 243.028 | 1 | [Fuc(SO3H)-H]− | 695.195 | 1 | [Fuc3(SO3H)3-H]− |
| 279.707 | 3 | [Fuc4(SO3H)3-3H]3− | 521.136 | 1 | [XylFuc2(SO3H)-H]− |
| 307.053 | 2 | [Fuc3(SO3H)2-2H]2− | 653.183 | 1 | [Xyl2Fuc2(SO3H)-H]− |
Figure 3Negative-ion mode electrospray mass spectrometry in tandem with collision-induced dissociation tandem mass spectrometry (ESI-CID-MS/MS) spectra of the ion at m/z 403.089 (−1) (A), 565.141 (−1) (B), 330.024 (−2) (C), 581.136 (−1) (D), and 889.244 (−1) (E).
Figure 4Negative-ion mode ESI-MS spectrum of ST-2-S.
Figure 5The DEPTQ NMR spectrum (A), the 13C NMR spectrum (B), the 1H NMR spectrum (C), and the HSQC spectrum (D) of ST-2-L.
Figure 6The proposed structure scheme of ST-2-L.
Figure 7Anti-tumor activities of polysaccharides (ST-2, ST-2-H, and ST-2-L) against human lung cancer A549 cells (A) and anti-angiogenic activities against human umbilical vein endothelial cells (HUVEC) (B). The results are expressed as percent inhibition. Data are the mean of three determinations +/− SEM.